12.01.2018 17:30:37

Concert Pharmaceuticals Neutral

Der Analyst Mizuho hat Concert Pharmaceuticals Inc von Buy auf "Neutral" abgestuft, aber das Kursziel auf 23 belassen..
Zusammenfassung: Concert Pharmaceuticals Inc Neutral
Unternehmen:
Concert Pharmaceuticals Inc
Analyst:
Mizuho
Kursziel:
$ 23.00
Rating jetzt:
Neutral
Kurs*:
23.00 €
Abst. Kursziel*:
0.00
Rating update:
downgrade
Kurs aktuell:
$ 19.24
Abst. Kursziel aktuell:
19.54%
Analyst Name::
-
KGV*:
-
* Zum Zeitpunkt der Analyse

Analysen zu Concert Pharmaceuticals Incmehr Analysen

12.01.18 Concert Pharmaceuticals Neutral Mizuho
26.10.17 Concert Pharmaceuticals Buy Mizuho
24.07.17 Concert Pharmaceuticals Buy H.C. Wainwright & Co.
07.03.17 Concert Pharmaceuticals Buy Stifel, Nicolaus & Co., Inc.
01.07.16 Concert Pharmaceuticals Buy Stifel, Nicolaus & Co., Inc.

Eintrag hinzufügen

Aktien in diesem Artikel

Aktuelle Aktienanalysen

16.01.18 Barclays Capital
YUM! Brands Equal weight
16.01.18 Barclays Capital
Wingstop Equal weight
16.01.18 Barclays Capital
The Wendys overweight
16.01.18 Barclays Capital
The Cheesecake Factory Equal weight
16.01.18 Barclays Capital
Texas Roadhouse overweight
16.01.18 Barclays Capital
Starbucks Equal weight
16.01.18 Barclays Capital
Sonic Underweight
16.01.18 Barclays Capital
Shake Shack Equal weight
16.01.18 Barclays Capital
McDonalds overweight
16.01.18 Barclays Capital
Jack in the Box Equal weight
16.01.18 Barclays Capital
Dunkin Brands Group overweight
16.01.18 Barclays Capital
Dominos Pizza Equal weight
16.01.18 Barclays Capital
Darden Restaurants overweight
16.01.18 Barclays Capital
Chipotle Mexican Grill Equal weight
16.01.18 Barclays Capital
Brinker International Equal weight
16.01.18 Barclays Capital
BJs Restaurants Underweight
16.01.18 Barclays Capital
United Natural Foods Equal weight
16.01.18 Barclays Capital
Smart & Final Stores overweight
16.01.18 Barclays Capital
US Foods Equal weight
16.01.18 Deutsche Bank AG
Newmont Mining Hold
16.01.18 Deutsche Bank AG
Vale Hold
16.01.18 UBS AG
SS&C Technologies Buy
16.01.18 UBS AG
JPMorgan Chase & Buy
16.01.18 UBS AG
HP Neutral
16.01.18 The Benchmark Company
Invitae Buy
16.01.18 The Benchmark Company
Natus Medical Buy
16.01.18 Macquarie Research
Rio Tinto Outperform
16.01.18 Wedbush Morgan Securities Inc.
Spark Therapeutics Underperform
16.01.18 Norddeutsche Landesbank (Nord/LB)
Deutsche Bank Halten
16.01.18 DZ BANK
Swiss Re kaufen
16.01.18 Goldman Sachs Group Inc.
Walmart Neutral
16.01.18 Barclays Capital
Credit Suisse Grou Underweight
16.01.18 Canaccord Adams
Primero Mining Hold
16.01.18 Seaport Global Securities
AAR Buy
16.01.18 Gabelli & Co
Kirby Hold
16.01.18 Aegis Capital
Twitter Buy
16.01.18 H.C. Wainwright & Co.
Fibrocell Science Buy
16.01.18 H.C. Wainwright & Co.
Pieris Pharmaceuticals Buy
16.01.18 H.C. Wainwright & Co.
Valeant Pharmaceuticals International Buy
16.01.18 Needham & Company, LLC
Hill-Rom Buy
16.01.18 Needham & Company, LLC
AtriCure Buy
16.01.18 JP Morgan Chase & Co.
HUGO BOSS Neutral
16.01.18 S&P Capital IQ
BP Hold
16.01.18 DZ BANK
Aurubis (ex Norddeutsche Affinerie) Halten
16.01.18 H.C. Wainwright & Co.
Sorrento Therapeutics Buy
16.01.18 Norddeutsche Landesbank (Nord/LB)
Drägerwerk vz kaufen
16.01.18 Morgan Stanley
HUGO BOSS Underweight
16.01.18 Craig Hallum
TPI Composites Buy
16.01.18 DZ BANK
Südzucker Halten
16.01.18 Needham & Company, LLC
SecureWorks a Hold